Phase 0/I/II Cancer Prevention Clinical Trials Program Clinical Trials

Titlesort descending Intervention NCT ID Sponsor Status
Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers Laboratory Biomarker Analysis, Questionnaire Administration, Dolcanatide, Placebo Administration NCT03300570 National Cancer Institute (NCI) Active, not recruiting
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Erlotinib NCT02273362 National Cancer Institute (NCI) Active, not recruiting
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous... Erlotinib Hydrochloride, Erlotinib NCT02961374 National Cancer Institute (NCI) Active, not recruiting
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial... Exemestane, Laboratory Biomarker Analysis, Questionnaire Administration, Pharmacokinetic Study NCT03300557 National Cancer Institute (NCI) Recruiting
Iloprost in Preventing Lung Cancer in Former Smokers Iloprost, Quality-of-Life Assessment, Questionnaire Administration, Placebo Administration NCT02237183 National Cancer Institute (NCI) Active, not recruiting
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Laboratory Biomarker Analysis, Metformin Hydrochloride NCT02581137 National Cancer Institute (NCI) Active, not recruiting
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer MUC1 Peptide-Poly-ICLC Vaccine, Laboratory Biomarker Analysis NCT03300817 National Cancer Institute (NCI) Recruiting
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure NCT02636582 National Cancer Institute (NCI) Active, not recruiting
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Therapeutic Conventional Surgery NCT00118040 National Cancer Institute (NCI) Active, not recruiting
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Questionnaire Administration, Z-Endoxifen Hydrochloride, Placebo Administration NCT03317405 National Cancer Institute (NCI) Active, not recruiting

Pages